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ABSTRACT 
Traditional medicines prepared from Sutherlandia frutescens are used to manage 
diseases including HIV and cancer.  This study aimed at isolating and identifying 
biologically active compounds isolated from S. frutescens. 
Sutherlandia frutescens plants were collected in Petrusburg and Paarl.  Powdered 
plant material was extracted using ethanol or water and their metabolite composition 
was compared using UPLC-MS.  A novel cycloartane, an acetylated variant of this 
compound as well as a Sutherlandioside B triterpenoid was isolated and 
characterised using chromatographic and analytical techniques such as NMR and 
UPLC-MS. 
Preliminary biological studies were conducted to assess the activity of plant extracts 
on cell toxicity, herpes virus replication and cytokine expression.  The results of this 
study suggest that aqueous extracts from S. frutescens do not appear to be cytotoxic 
or show anti-herpetic activity, but may activate the immune system by increasing 
expression of IL-6, IL-10 and TNFα.  Further research should be conducted to 
confirm and optimise these results. 
 
Key terms 
Sutherlandia frutescens, traditional medicine, NMR, UPLC-MS, HIV, AIDS, 
Cytokines, Immunomodulation, Cytometric bead arrays, flow cytometer. 
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CHAPTER 1:  INTRODUCTION 
 
1.1 Human immunodeficiency virus and immune system 
Human Immunodeficiency Virus (HIV) is an agent that causes Acquired 
Immunodeficiency Syndrome (AIDS).  Infection with HIV is epidemic and results in 
immunosuppression that allows opportunistic infections and malignancies.  There 
are two types of HIV with HIV-1 being the more pathogenic of the two.  
Consequently, there is a great demand for new therapeutics to this virus (Cos et al., 
2002).  
Fundamental to the pathogenesis of HIV-1 is the infection and subsequent depletion 
of CD4
+ T cells.  This leads to a steady drop of peripheral blood CD4
+ T cell counts 
during chronic infection, a characteristic of individuals infected with HIV-1.  Most of 
the CD4
+ T cells are located in the lymphoid tissues, such as the lymph nodes and 
particularly the mucosal lymphoid tissues within the gastrointestinal tract (Appay & 
Sauce, 2008).  Unlike HIV-1, disease progression in HIV-2-infected individuals is 
slower and most patients die from HIV-2-unrelated causes (Sousa et al., 2002).  
However, infection with HIV-2 also shows a decline in both the functionality and the 
number of CD4
+ lymphocytes with associated loss of immune competence eventually 
leading to AIDS (Roshal et al., 2001; Sousa et al., 2002). 
The host immune system provides protection against a variety of constantly evolving 
pathogenic microbes and it also helps the host to get rid of toxic and allergenic 
substance that enter through mucosal surfaces (Chaplin, 2010).  A major role is 
played by cytokines and chemokines in the host defence against microbes, including 
HIV (Alfano & Poli, 2005) where cytokines (IFN-𝛾, IL-6, IL-12, and TNF; alternatively 
IL-4, IL-10 or IL-13) are released from activated macrophages during early stages of 
infection or tissue damages (Chaplin, 2010; Parkin & Cohen, 2001). 
Both innate and adaptive immune responses combine to form the main two parts of 
immunity (Parkin & Cohen, 2001). The innate response includes barriers such as 
skin as well as small bioactive molecule (including cytokines and chemokines) and 
soluble proteins that are released as the immune response is activated by pathogens 
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(Chaplin, 2010) and provides an immediate host defence (Parkin & Cohen, 2001).  
Unlike the innate immune system, the adaptive response is highly specific and has 
memory of previously encountered microbes (Parkin & Cohen, 2001).  It might also 
take several days or weeks to become prominent after antigen-specific T and B cells 
have undergone clonal expansion.  Synergy between the innate immune system and 
adaptive immune system is essential for a fully effective immune system (Chaplin, 
2010). 
Due to the high cost of standard antivirus therapeutics, most Africans resort to 
traditional medicines as an alternative treatment for the management of HIV/AIDS 
(Moshi, 2005).  In spite of the possibility of harm and relatively little evidence of 
effectiveness of traditional medicines, such therapeutics are believed to be 
extensively used among people living with HIV and in many African nations the 
Ministries of Health endorse the use of traditional medicines for the treatment of HIV 
and related ailments (Mills et al., 2005a). 
 
1.2 Traditional medicines 
In many African countries, more than 80% of the population living in rural areas use 
traditional medicines in spite of an apparent lack of scientific evidence for their 
quality, safety and efficacy (Elujoba et al., 2005; Mills et al., 2005b).  Due to 
limitations regarding resources and access to reliable modern medical services, 
many Africans visit traditional practitioners for their health care needs and  traditional 
medicines are used as a treatment for a wide range of ailments including HIV/AIDS, 
malaria, sickle cell anaemia, diabetes and hypertension (Kayne, 2009; Okigbo et al., 
2006).  
In Africa, traditional medicines were the dominant medical system prior to the 
introduction of western medicines.  Traditional medicines form part of the solution for 
many health challenges as they are considered safe, affordable and have fewer side 
effects when compared to conventional medicines (Moshi, 2005; Okigbo et al., 
2006).  A significant proportion of citizens in industrialised countries like Germany 
(75%), Canada (70%) and England (47%) regularly use traditional medicines 
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(Kayne, 2009). Unless complemented by traditional medicines, effective health in 
Africans cannot be achieved with modern medicines alone (Elujoba et al., 2005). 
Bioactive compounds found in various parts of plants such as roots, leaves, stems, 
flowers, seeds or bark play a significant role in the management of diseases and 
these phyto-compounds are also a good source of plant-derived drugs (Moshi, 
2005).  Examples include the isoquinoline alkaloid, emetine, which is isolated from 
an underground part of the plant Cephaelis ipecacuanha.  This compound is 
classified as anti-infective and for many years, related species have been used as an 
amoebicidal drug as well as for treatment of abscesses resulting from the spread of 
Entamoeba histolytica infection (Iwu et al., 1999). While synthetic or chemical drugs 
may have a greater and faster effect compared to phyto-medicines, they 
nevertheless may present a higher degree of side effects and risks (Okigbo et al., 
2006).  Alternatively,  drug development from a natural source is often more difficult 
than synthetic drug development (Elujoba et al., 2005) as there are often several 
manufacturing problems encountered when designing formulations of herbal 
medicines.  These challenges include failure of good manufacturing practice, 
misidentification of plants, microbial contamination in the field, lack of 
standardization, poor packaging, chemical usage and the deleterious effects of 
environmental conditions such as temperature and exposure to light (Calixto, 2000; 
Elujoba et al., 2005).  In spite of these problems, the South African Ministry of Health 
endorses the use of two herbal remedies for the management of HIV, Sutherlandia 
frutescens (S. frutescens) and Hypoxis hemerocallidea (common name: African 
potato) (Mills et al., 2005a). 
 
1.3 Biotopes 
Standardisation of plant-based pharmaceutical products is affected by varying 
chemical compositions which may be dependent on geographical location.  To 
assess the metabolite content, Albrecht et al., (2012) studied S. frutescens growing 
in different geographical environments.  The use of LC-MS in these studies indicated 
varying concentrations of sutherlandioside B (SU1) in S. frutescens extracts.  Of the 
two locations studied (the arid Karoo and the coastal Gansbaai), virtually 
4 
 
undetectable levels of SU1 were observed in extracts obtained from the Gansbaai 
populations. 
 
1.4 Problem statement 
Sutherlandia frutescens, also known as cancer bush, is a plant species indigenous to 
South Africa that is well known for its medicinal properties where extracts of the 
leaves contain many medicinal properties.  Nevertheless, little is known about the 
bioactive compounds existing in such leaf and seed extracts (Shaik et al., 2010). 
Pharmacognosy has provided sufficient scientific evidence to the pharmaceutical 
industry so that phyto-compounds obtained from long-used and purported medical 
plants have great potential for the development of novel drugs (Phillipson, 2007).  
The vast majority of the African population still use traditional medicinal plants for 
healing of many ailments because they are regarded as safe for consumption, are 
more affordable, are convenient and easy to access and can be used for a long time 
(Vermani & Garg, 2002). 
The bioactive phyto-compounds used in the management of ailments may be found 
in various parts of the plant, such as roots, leaves, flowers, seed or bark.  However, 
chemical and genetic inconsistency in plants from different geographical biotopes 
complicates the standardization of commercially available end product (Bourgaud et 
al., 2001). 
Herbal remedies are used for their immune-boosting abilities among HIV-infected 
individuals but concomitant administration with antiretroviral medication is known to 
have side effects (Bepe et al., 2012; Brown et al., 2008).  Therefore, there is a need 
to study this species to show its potential as a source of medical phyto-compounds, 
to identify the bioactive compounds and to compare plants obtained from different 
geographical areas. 
It is necessary, then, to validate claims that have been made about the medicinal 
properties of S. frutescens plant extracts.  To this end, extracts were prepared from 
S. frutescens and isolated compounds were identified and screened for immune-
boosting, cytotoxicity and antiviral activity. 
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1.5 Purpose of the study 
The aim of this study is to isolate compounds present in various S. frutescens plant 
extracts and to determine the biological activity of these compounds. 
 
1.6 Research Objectives 
 To investigate S. frutescens collected from at least two different geographical 
areas  
 To use physico-chemical techniques such as liquid chromatography and 
nuclear magnetic resonance to characterise compounds isolated from these 
plants. 
 To compare the biological activity of compounds isolated from S. frutescens 
plants from the two regions. 
 To investigate the effect of such compounds on cytotoxicity, anti-herpes 
replication and their effect on cytokine production in blood cells. 
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CHAPTER 2:  LITERATURE REVIEW 
 
2.1 Medicinal Plants 
South Africa is rich in plant diversity and the use of traditional medicines is extensive 
and endorsed by its Ministry of Health.  There are about 200 000 indigenous 
traditional health practitioners in South Africa and in addition to using modern 
biomedical services, up to 80% of the population consult these traditional healers 
(Kasilo et al., 2010; Van Wyk et al., 2005).  Medicinal plants are an essential part of 
the South African cultural heritage and plant-derived medicines form a large part of 
daily medicine for South African citizens.  Due to the rich cultural diversity in South 
Africa, formal and informal systems of medicines are currently practised in different 
parts of the country and large volumes of such medicines are sold both in the 
informal and commercial sectors of the economy as plant material or as extracts 
(Van Wyk et al., 2005).  Medicinal plants consist of mixtures of compounds that may 
act to improve health and these compounds may act individually, additively or in 
synergy (Van Wyk & Wink, 2004). 
Over 24 000 species of higher plants are found in South Africa, with nearly 9 000 
species belonging to the Cape Floral Kingdom.  Owing to this bio- and cultural 
diversity, South Africa has approximately 3 000 plants species used as medicines.  
Better understanding of the healing power of plants has been gained through treating 
complicated health conditions.  The Khoi-San, the Nguni and the Sotho-speaking 
people use an informal oral-traditional medicine system which has not yet been 
documented sufficiently and, hence, knowledge is passed on from one generation to 
the next by word of mouth (Van Wyk et al., 2005; Van Wyk & Wink, 2004). 
In many societies, traditional and allopathic medicines are used side by side to 
complement each other with the allopathic medicines being used to treat serious and 
acute health conditions while traditional medicines are mostly used for treating 
chronic infections to reduce symptoms and improve the quality of life in a cost-
effective way (Van Wyk & Wink, 2004). 
7 
 
2.2 Sutherlandia frutescens 
Sutherlandia frutescens is a South African legume which has been traditionally used 
as an indigenous medicine for an assortment of diseases (Ojewole, 2004).  The 
genus Sutherlandia belongs to the order Galegeae and is closely related to the 
genera Astragalus L. and especially Lessertia DC (Van Wyk & Wink, 2004) and  
belongs to the subspecies: Microphylla, family: Fabaceae/Leguminosa (Fernandes et 
al., 2004). 
 
 
Figure 1: Sutherlandia frutescens (www.infonet-
biovision.org/default/ct/202/medicinalplants) 
 
Physically, S. frutescens is a flat to erect, perennial shrub that grows up to 3 m in 
height.  Stems are glabrous, with many leaves near the tips.  The leaves are slightly 
to densely hairy, petiolate, stipulate and pinnate.  The S. frutescens plant has bright 
red, tube-like flowers of up to 35 mm which are “markedly compressed laterally, with 
oblong, boat-shaped keel petals, two tiny wing petals and a large, apically recurved 
standard petal, typically marked with white lines.  The typical fruits are large and 
seeds are dark brown with a diameter of about 3 mm” (Van Wyk & Wink, 2004). 
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2.2.1 Medicinal uses of Sutherlandia 
Sutherlandia frutescens is a variable plant species endemic to southern Africa 
including the southern parts of Namibia, the southern regions of Botswana, the 
western, central and eastern parts of South Africa and most of Lesotho (Van Wyk & 
Wink, 2004).  This plant has been used medicinally for many years and it was 
originally used by the Khoi San and Nama people, who used it mostly as an extract 
for the washing of wounds (Van Wyk & Albrecht, 2008).  Zulu warriors also used the 
plant to relax themselves after battle (Faleschini et al., 2013;  Van Wyk & Albrecht, 
2008). 
 
 
Figure 2: Geographical distribution of S. frutescens (Berend, 2000)  
 
Sutherlandia frutescens is a multi-purpose medicinal plant and is used as a 
supplement for diseases such as diabetes and chronic depression along with HIV-
infection management (Van Wyk & Gericke, 2000).  It is a useful bitter tonic and is 
normally taken before meals to help with digestion and to improve the appetite.  In 
addition, tinctures, infusions and decoctions of the leaves and young stems of S. 
frutescens have been used to treat colds, influenza, asthma, tuberculosis, bronchitis, 
rheumatism, rheumatoid arthritis and osteoarthritis, liver problems, haemorrhoids, 
piles, bladder, uterus and 'women's complaints', diarrhoea and dysentery, stomach 
ailments, heartburn, peptic ulcers, backache, diabetes, varicose veins and 
inflammation (Ojewole, 2004). 
Extracts have also been shown to have anti-bacterial, anti-oxidant (Katerere & Eloff, 
2005), anti-inflammatory (Kundu et al., 2005) stress-relieving (Prevoo et al., 2008) 
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blood sugar-reducing (Chadwick et al., 2007), anti-tumour (Stander et al., 2007) and 
anti-mutagenic (Reid et al., 2006) activities.  Ngcobo et al. (2012) showed that the 
addition of low concentrations of extracts of S. frutescens on a primary culture of T 
cells could stimulate immune responses.  Literature reports have also revealed that 
extracts from S. frutescens can also be used in the treatment of HIV/AIDS (Harnett 
et al.,  2005; Mills et al., 2005b), cancer (Chinkwo, 2005; Stander et al., 2007; Tai et 
al., 2004) as well as to treat diabetes (Chadwick et al., 2007; Sia, 2004). 
The anti-cancer and anti-viral properties of extracts from S. frutescens have been 
attributed to the presence of L-canavanine (Green, 1988) because high doses of this 
compound blocks DNA synthesis in vitro and at low concentration affects B-cell 
function in autoimmune mice.  Other in vitro studies have shown that L-canaline, a 
small non-protein amino acid, is cytotoxic to human peripheral blood mononuclear 
cells (PBMCs) through the disruption of polyamine biosynthesis (Bence et al., 2002).  
Brown et al., (2008) investigated the effect of aqueous extracts of two traditional 
medicinal plants, Hypoxis hemerocallidea and S. frutescens, including L-canavanine 
isolated from S. frutescens, on transportation of nevirapine across human intestinal 
epithelial cell.  A combination of an antiretroviral drug and an extract of H. 
hemerocallidea or of L-canavanine led to inhibition of nevirapine efflux – i.e. these 
compounds led to a decreased transport in the basolateral (BL) to apical (AP) 
direction across Caco-2 cell monolayers as compared to movement in the AP to the 
BL direction (Brown et al., 2008).  This study also showed that an extract of S. 
frutescens also has an effect on nevirapine efflux but which was reduced in 
comparison with that of H. hemerocallidea and L-canavanine.  However, the high 
inhibiting effects of L-canavanine were ascribed to the high doses used and an 
associated increase in the bio-availability of nevirapine was then observed. 
The toxicity of S. frutescens (SF) was established by examining the effects of 
extracts in 70% ethanol (SFE) and deionised water (SFW) on normal, isolated 
human T cells.  The toxicity of SF extracts was dose- and time-dependent, with SFE 
fractions being more potent in inducing cell death over 48 hours.  High doses of S. 
frutescens were cytotoxic to the normal T cells following induction of necrotic cell 
death resulting in exhaustion of cellular ATP, inhibition of caspase-3/-7 activity and 
induction of DNA fragmentation (Ngcobo et al., 2012). 
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At low doses, S. frutescens influences gene expression and alters metabolic activity.  
Extracts of S. frutescens have anti-diabetic properties in animal models and studies 
done on a human liver cell cultures and it can also prevent insulin resistance in 
hepatocytes (Williams et al., 2013).  Vorster et al., (2012) reported that S. frutescens 
extracts affect the proliferation, morphology and cell cycle dynamics of both the 
MCF-7 breast adenocarcinoma and MCF-12A breast epithelial cell lines to varying 
degrees in a time- and dose-dependent manner.  The MCF-7 carcinoma cell line was 
more susceptible to the cytotoxic effects of aqueous extracts of S. frutescens when 
compared to the MCF-12A cell line. In addition, S. frutescens extracts has immune 
modulating as well as anti-inflammatory activities in vitro (Vorster et al., 2012). 
 
2.2.2 Compounds isolated from Sutherlandia species 
Chemical studies conducted on this plant species have revealed that aerial parts of 
S. frutescens contain several bioactive chemical compounds including L-canavanine, 
Gamma-aminobutyric acid (GABA), D-pinitol, asparagine, methyl- and propyl-
parabens, flavonoids and small amount of saponins including novel triterpernoid 
glycosides (sutherlandioside A-D) (Avula et al., 2010; Fu et al., 2008; Van Wyk & 
Gericke, 2000).  Compounds such as GABA, L-canavanine, L-arginine, D-pinitol and 
a glycan have been proposed as being responsible for this bioactivity.  Amino acids 
make up about 10% to 15% (w/w) of dried plant material and the most abundant 
amino acids are proline, L-asparagine L-canavanine and alanine, which collectively 
represent approximately 60% of the total amino acid content.  However, not all plant 
samples contained all these amino acids (Mncwangi & Viljoen, 2012). 
 
2.2.2.1 Canavanine 
Canavanine, or L-2-amino-4(guanidine-oxy)butyric acid, is a structural analogue of 
arginine and is a potential competitor for L-arginine.  It is often found in seeds of 
Fabaceae plants (Mills, 2005) and has anti-cancer and anti-viral activity, as well as 
inhibition of influenza virus and retroviruses (Green, 1988).  Between 30 mg and 40 
mg of canavanine can be found per dry gram of the S. frutescens leaves (Van Wyk & 
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Gericke, 2000; Gericke et al., 2001).  Canavanine is an inhibitor of nitric oxide 
synthase and this effect may be useful in treating certain forms of heart failure (Van 
Wyk & Gericke, 2000). 
 
 
Figure 3: Structural formula of canavanine 
 
 
2.2.2.2 Gamma Amino Butyric Acid (GABA) 
This is a non-essential amino acid found in the leaves of S. frutescens and it is an 
inhibitory neurotransmitter (Ngcobo, 2008).  It is synthesized by decarboxylation of 
glutamate by the enzyme L-glutamic acid-1-decarboxylase (Ebadi, 2007). Gamma 
amino butyric acid has been used to treat epilepsy and hypertension (Balch, 2006).  
Together with inositol and niacinamide (vitamin B3), GABA inhibits anxiety- and 
stress-related neuron messages from reaching the motor centres of the brain by 
occupying their receptor sites.  Consequently it is critical for brain metabolism, where 
its function is to decrease neuron activity and prevent nerve cells form over-firing 
(Balch, 2006). 
 
 
Figure 4: Structural formula of GABA  
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2.2.2.3 Pinitol 
This is a form of sugar found in legumes and is characterised as chiro-inositol.  The 
biological activity of pinitol makes S. frutescens a potentially essential traditional 
remedy in treating diabetes and inflammation (Moshe et al., 1998).  It has been used 
to treat wasting in cancer as well as AIDS and is identified as an anti-diabetic agent 
(Narayanann et al., 1987; Ostlund & Sherman, 1996).  Pinitol possesses an insulin-
like effect (hypoglycaemic effect) which lowers blood glucose levels to increase 
bioavailability of glucose for cell metabolism (Bates et al., 2000).  It also increases 
the retention of creatinine and glucose absorption by muscle cells (Greenwood et al., 
2001).  Consequently pinitol benefits sporting enthusiasts, who have simultaneous 
desires for strength and endurance, together with the additional benefits of 
shortened physiological recovery times. 
 
 
Figure 5 Structural formula of pinitol   
 
2.2.2.4 Flavonoids 
Flavonoids are phenolic compounds that occur naturally in fruits, vegetables and 
certain beverages such as tea and wine and have diverse antioxidant effects.  
Flavonoids also have both in vitro and in vivo anti-allergic, anti-inflammatory, antiviral 
and anticancer activity (Middleton, 1998).  Avula et al. (2010) identified four 
flavonoids (sutherlandins A-D) in an attempt to provide chemical markers for the 
aerial parts of S. frutescens.  The four sutherlandins are shown in figure 6 below. 
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A: R = OH (1)      B: R = OH (2) 
C: R = H (3)       D: R = H (4) 
Figure 6: Structural formula of sutherlandins A to D  
 
2.2.2.5 Cycloartane glycosides 
These types of compounds are derived from a 30-carbon compound and are 
characterised by a complex structural conformation due to their secondary ring 
formations and the addition of chemical groups such as glucose.  Fu et al., (2008) 
identified four cycloartane glycosides called sutherlandiosides A – D while  Olivier et 
al., (2009) isolated another cycloartane-type triterpene glycoside called SU3 which is 
the first cycloartane diglycoside isolated from S. frutescens. 
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sutherlandioside A (7)    sutherlandioside B (5) 
 
 
sutherlandioside C (6)    sutherlandioside D (8) 
 
 
SU3 (9) 
Figure 7: Structural formulas of sutherlandioside A to D (5-8) 
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2.2.3 Various activities attributed to Sutherlandia frutescens extracts 
 
2.2.3.1 Immunomodulation 
The immune system’s basic function is to protect an individual against infectious and 
potential pathogens.  Immunomodulation is a modification of the immune response 
to a particular level by agents that activate or suppress its function. The 
enhancement of immune responsiveness is known as immunostimulation and the 
reduction in immune responsiveness is known as immunosuppression (Mukherjee et 
al., 2014).  Cytokines are secreted by cells in response to a stimulus and are the 
central mediator of inflammation and specific immune responses.  Because of the 
role they play in modulation of HIV gene expression of infected cells they are 
assumed to be major role players in the pathogenesis of HIV (Estcourt et al., 1997).  
The type of immune response is determined by three components: the nature of the 
antigen; by regulatory T cells and the cytokines products of these T cells.  
Natural products used for medicinal purposes can serve as alternate 
immunomodulatory and therapeutic agents that help to boost the body’s defence 
mechanism.  Immunostimulatory and immunomodulatory properties are commonly 
found in plants used in traditional medicine preparations.  Such effects play a vital 
role in modifying the immune response to fight infections such as HIV and AIDS 
(Bodeker et al., 2006).  Faleschini et al., (2013) observed that non-polar compounds 
from an ethanol extract of S. frutescens could amplify the release of specific 
immune-modulating cytokines, and this was particularly evident in cells which were 
stimulated by pathogenic microorganisms such as gram negative bacteria. 
Three cytokines, namely IL-10, IL-6 and TNF-α, were reported by Stenvinkel et al., 
(2005) to be the crucial factors in the altered cytokine network of uremia and might 
also be involved in the development of cardiovascular disease, an inbalance in Th 
cells and worsening in the uremic milleu.  In a study performed by Havlir et al., 
(2001), these three cytokines as well as others were elevated in HIV-1-infected 
persons with an advanced immune deficiency.  It was then proposed that the 
elevation of these serum cytokines was due to advanced immune deficiency (Havlir 
et al., 2001).  A focus of the current study involves these three cytokines, viz. IL-10, 
IL-6 and TNF-α. 
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2.2.3.2 Anti-oxidant activity 
Anti-oxidant micronutrients such as alpha tocopherol and beta carotene improve the 
production and activity of cytotoxic immune cells that express cytokines that can 
terminate cancer cells and, hence, these micronutrients can inhibit, prevent or 
regress cancer in vitro (Shklar, 1998).  Fernandes et al., (2004) observed that hot 
water extracts of S. frutescens possess potent antioxidant activity and could be 
compared with some teas such as rooibos where similar activity was also observed. 
 
2.2.3.3 Antibacterial activity 
Hexane extracts of S. frutescens showed a reasonable activity against both S. 
aureus and E. faecalis as compared to other extracts (Eloff et al., 2005).  Its activity 
compares well with other extracts from plants such as Combretum species and the 
high activity of the hexane extract might be attributed to the presence of active 
compounds in high concentration (Katerere & Eloff, 2005).  The activity of S. 
frutescens against S. aureus suggests that it could possibly be used in topical 
applications and reports of its use as a crude form of commercial product have been 
published (Gericke et al., 2001).  A study performed by Katerere & Eloff (2005) 
showed that non-polar compounds possess an anti-staphylococcal activity and, 
hence, it may be necessary to use non-polar solvents for optimum therapeutic 
benefit. 
 
2.2.3.4 Anti-cancer activity 
The incidence of cancer has been increasing worldwide despite the substantial 
progress made in developing anti-cancer therapies.  Chemoprevention has been 
reported in the literature as one of the most rational approaches in reducing the risk 
of cancer and this strategy is relatively new and promising (Kundu et al., 2005).  
Chemoprevention is the use of non-toxic substances to block, prevent or to retard 
tumorigenesis and these substances can be natural, be synthetic in origin or be a 
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combination of the two.  Phytochemical compounds derived from plants can interfere 
with specific stages of carcinogenesis (Young-Joon, 2003).  
Due to the historical use of Sutherlandia as an anti-cancer agent, Tai et al., (2004) 
investigated its anti-proliferative effects on several human tumour cell lines.  Different 
anti-proliferative effects were observed on breast and leukemia cell lines with a 
higher activity against MDA-MB-468 breast cells compared to Jurkat and HL60 
leukemia cells (Tai et al., 2004). 
 
2.2.3.5 Anti-HIV activity 
An effective HIV inhibitor requires at least two key activities:  inhibiting the interaction 
between viral and cellular receptors at the surface of a cell and blocking the viral 
transmembrane gp 41 protein so as to prevent cell fusion and, hence, block cell-to-
cell transmission of HIV.  Mechanistically, most of the effective natural or natural-
based products (e.g. dextran sulphate) interact with the viral gp 120 to then 
competitively inhibit the binding of gp 120 to the CD4 recognition site on the T-
lymphocytes cell surface (Yang et al.,2001).   
As an inexpensive herbal remedy, S. frutescens has gained international recognition 
as a source of agents that may improve the health of HIV/AIDS patients.  As a 
source of antiviral activity, this plant is reported by doctors and healthcare workers to 
contain compounds that improve CD4 cell counts, decrease viral loads, improve 
appetite, improve mood and prompt an increase in patient weight  (Chaffy & Stokes, 
2002).  Harnett, et al., (2005) observed significant inhibition (64%) in a HIV- reverse 
transcriptase (RT) assay involving Sutherlandia and Lobostemon extracts, 
regardless of the loss of inhibition that may have resulted due to the removal of 
sulphated polysaccharides and the addition of bovine serum albumin (BSA).  Hence, 
the inhibitor may be a novel compound and not a polysaccharide or tannin 
compound (Harnett et al., 2005). 
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2.2.3.6 Pharmacokinetics and pharmacology 
The pharmacokinetic properties of S. frutescens have not been extensively 
assessed.  Thus, when Mills et al., (2005) used in vitro studies to assess the effect of 
S. frutescens on CYP3A4, P-gp and PXR, a close to complete inhibition of CYP3A4 
(96%) was noted while only moderate activity of P-gp was observed. Comparatively, 
this showed a 19-31% activity strength relative to verapamil and a more than two-
fold activation that was dose-dependent was observed for PXR under exposure to S. 
frutescens (P <0.01) (Mills et al., 2005). 
 
2.2.4  Theory and practice of analytical techniques used in this study 
Isolation and structural elucidation of secondary metabolites from traditional 
medicines is a crucial part of the production of herbal infusions and is achieved 
through taking advantage of analytical techniques.  Secondary metabolites facilitate 
critical phenomena such as metabolism, signal transduction, mating attraction, and 
chemical defence (Robinette et al. 2012).  In the current study 1D (1H, DEPT, 13C) 
and 2D (COSY, HSQC, HMBC) nuclear magnetic resonance (NMR) experiments 
were used for structural elucidation.  The UPLC-QTOF-MS also assisted in structure 
elucidation by providing accurate mass and fragmentation patterns of the isolated 
compounds. 
Nuclear magnetic resonance spectroscopy is a qualitative technique used for quality 
control, structural elucidation and to assess purity of samples.  It uses one to three 
dimensional approaches, namely one dimension (1D), two dimensions (2D) and 
three dimensions (3D) for structural elucidation of organic compounds (Fuloria and 
Fuloria, 2013).  It is an analytical technique that takes advantage of the intrinsic 
magnetic properties that are associated with atomic nuclei with odd numbers of 
protons and/or neutrons.  When a sample of unknown compound with such nuclei is 
placed in a large magnetic field and subjected to the radio-frequency (rf) field of the 
oscillator, it then absorbs the rf energy which causes it to align and rotate to lie 
parallel with the field.  The strength of the magnetic field and the rf signal is picked 
up by a detector (Elad et al., 2012).  In this study two Varian NMR instruments 
allowing analysis at 600 MHz and 400 MHz were used. 
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Although NMR analysis is the most suitable source of information for structural 
elucidation it still needs to be complemented by other techniques like the Mass 
spectroscopy (UPLC-QTOF-MS).  Mass spectrometry is made out of three basic 
components: one that volatilizes and ionises the molecule in a beam of charged 
particles; another that focuses the beam so that particles of the same mass-to-
charge ratio are separated from all others and a third component that is used to 
detect the particles (Clayden et al., 2001; Robinette et al., 2012). 
Mass spectroscopy uses the difference in mass-to-charge ratio (m/z) of ionized 
atoms or molecules to separate them and structural information is acquired by 
identifying distinct fragments patterns (Clayden et al., 2001).  It operates by creating 
gas-phase ions followed by separation of ions in space or time based on their mass-
to-charge ratio and measures the quantity of ions of each mass-to-charge ratio. The 
applications in organic chemistry of MS includes determination of molecular mass, 
characterisation, confirmation of the identity and purity of a unknown samples and 
providing data on isotopic abundance (Bross-Walch et al., 2005; Clayden et al., 
2001). 
Flow cytometry was used to assess the immune-potentiating ability of plant extracts, 
fractions, and isolated compounds.  This is a laser-based technique that is used in 
counting and sorting of cells, in biomarker detection and in protein engineering 
(Davis, 2007).  This technique allows for simultaneous analysis and measurement of 
multiple physical and chemical characteristics of a single particle (e.g. cell) in a fluid 
sheath as it flows past a laser beam (Jahan-Tigh et al., 2012; Weaver, 2000).  A 
particle size of about 0.2-150 micrometre is required for analysis.  When the particles 
are fluorescently labelled, they emit light at varying wavelengths when excited by the  
laser energy (Jahan-Tigh et al., 2012; Weaver, 2000).  The dispersed fluorescent 
light is collected by positioned lenses and directed to the detectors using splitters 
and filters. Consequently, electronic signals are produced relative to the optical 
signals striking the detectors (Weaver, 2000). 
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CHAPTER 3:  ANALYSIS OF COMPOUNDS 
Traditional medicines form part of the solution for many health challenges and many 
traditional healers make use of infusions and decoctions of medicinal plants to treat 
many ailments.  As part of proof of concept and to assess the safety and efficacy of 
medicinal plants, phytochemical studies are usually conducted to scientifically mimic 
the action of traditional preparations. 
 
3.1 Materials and methods 
Column chromatography was used for the isolation of compounds.  Isolated 
compounds were characterised using a variety of analytical techniques such as 
nuclear magnetic resonance (NMR) spectroscopy (1D and 2D) and ultra-
performance liquid chromatography (UPLC)-time of flight (TOF)-mass spectrometry 
(MS). 
 
3.1.2 Plant Collection 
Aerial parts of S. frutescens were collected in Petrusburg, Free State, South Africa 
and in Paarl, Western Cape, South Africa.  The plant material was dried at 
ambient temperature and ground to a powder using a pin mill.  For identification, 
twigs containing flowers were sent to the South African National Biodiversity 
Institute (SANBI) and the plant species were identified as Sutherlandia 
frutescens (L.) R. B.r. (SANBI Genspec number: 462 and 602). 
 
3.1.3 Chemicals 
During the isolation of phytochemical compounds, various organic solvents such as 
ethanol, hexane, methanol and dichloromethane were used.  High quality CP grade 
solvents were purchased from Merck and distilled before use while for HPLC 
analysis, solvents were purchased from Microsep (Romil Chemistry, UK).  Solid 
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phase extraction C-18 cartridges (Supelco 140 ml PP tubes) were purchased from 
Sigma Aldrich. Distilled water was used for all procedures. 
 
3.1.4 Extract preparations 
A quantity of 600 g of plant material of S. frutescens from Petrusburg was divided 
into 3 x 200 g amounts and labelled A, C and E, respectively.  A different 
extraction method was used for each of these: for A, absolute ethanol; for C, 
70% ethanol and for E, distilled H2O.  Due to a relatively limited amount of 
material obtained from Paarl, 400 g of plant material was divided into 2 x 200 g 
amounts and labelled B and D that were then extracted with absolute ethanol 
and distilled H2O, respectively. 
Plant material from A and B was extracted three times with absolute ethanol (1.0 
L of 99.9% EtOH) overnight and the same procedure was followed for the 
extraction of C with 70% ethanol.  For aqueous extraction of D and E, plant 
material was boiled for 1 hour in 2.0 L distilled H2O with occasional stirring.  See 
Figure 8 below for a flow diagram indicating the extraction methods and 
percentage yields.  
 
 
 
 
 
 
    2.0 L absolute  20 L 70%              2.0 L H2O            2.0 absolute       2.0 L H2O 
    Ethanol   Ethanol/H2O             Boiled 1 hr            Ethanol       Boiled 1 hr 
    Overnight  Overnight              Filtered            Overnight       Filtered 
    Filtered   Filtered              Freeze dried            Filtered       Freeze dried 
    Evaporated  Evaporated & freeze dried             Evaporated 
 
 
 
Figure 8: Extraction methods 
Methods of Extraction 
Plant material from 
Petrusburg 
Plant material from 
Paarl 
Extract A  
51.3 g 
(25.6%) 
 
Extract C 
69.0 g 
(34.5%) 
Extract E 
31.69 g 
(15. 8%) 
Extract B 
15.2 g 
(7.6%) 
Extract D 
27.85 g 
(13.9%) 
22 
 
3.1.5 Liquid-Liquid partitioning 
An amount of 10 g of extract A was suspended in 100 ml of MeOH/H2O (ratio 9:1 
v/v) and sequentially extracted with hexane, dichloromethane (DCM) and ethyl 
acetate (EtOAc).  Four crude extracts and an emulsion phase were obtained as 
shown in Figure 9.  All the resulting organic extracts were evaporated to dryness 
using a rotary evaporator and the aqueous extracts were freeze-dried to give 
extracts A1 to A5. 
 
 
 
    1. Dissolve in 100 ml methanol-water (9:1)    
    2. Extract with 100 ml hexane x3    
            
            
            
            
            
            
                   
 Evaporate solvent    1. Evaporate methanol   
       2. Add 50 ml water   
       3. Extract with 100 ml DCM x3  
            
            
            
            
            
            
            Evaporate solvent     Extract with  
          100 ml EtOAc 
            
            
            
            
            
              
                 Evaporate solvent             Freeze dry 
            
      
 
 
Figure 9: Liquid-liquid flow diagram 
 
Extract A3 
3.13 g
Water layer 
Extract A2 
0.4157 g 
Emulsion layer 
(A3) 3.13 g 
EtOAc layer 
(A4) 1.13 g 
Water layer 
(A5) 3.25 g 
DCM layer (A2) 
0.416 g 
Extract A (10 g) 
Hexane layer 
(A1) 1.52 g 
Water layer 
Extract A1 
1.52 g 
Extract A4 
1.13 g 
Extract A5 
(3.25 g) 
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3.1.6 Isolation of compounds 5 and 10 
Extract A2 (415.7 mg) from the DCM extract was separated on a silica gel column 
using a stepwise gradient mixture of approximately 500 ml EtOAc/hexane (v/v) in the 
ratio 4:6, 5:5, 6:4, 8:2, 9:0 as an eluent to give 5 fractions.  Fraction 5 was 
chromatographed using preparative thin layer chromatography (prep-TLC) 
employing CHCl3/MeOH (9.5:0.5) as the eluent to give compound 10 (2.2 mg). 
Extract A3 from the emulsion phase was subjected to silica gel column 
chromatography using a stepwise gradient mixture of approximately 500 ml of 
CHCl3/MeOH (v/v) in ratio 10:0, 9:1, 7:3, 5:5, 4:6, 1:9 and 0:10 as an eluent.  Similar 
fractions were combined to give 7 fractions.  Fraction 1 was separated on a silica 
gel flash column and eluted with CHCl3/MeOH (10:0, 9:1, 7:3, 5:5, 0:10) and similar 
fractions were combined to give 5 fractions (labelled A-E).  A C-18 solid phase 
extraction (SPE) column (Supelco 140 ml PP tubes, Sigma Aldrich) was then used to 
purify fraction A and eluted with acetonitrile (ACN)/MeOH (10:0, 9:1, 7:3).  
Thereafter, prep-TLC was used to obtain compound 5 (6.9 mg) with 
EtOAc/MeOH/Acetic acid (9:1:1 v/v) as solvent system. 
 
3.1.7 Acetylation Procedure 
Acetylation of extract A3 (74.5 mg) samples was achieved by dissolving the extract 
in a mixture of pyridine-acetic anhydride (1:1) in a round-bottomed flask.  The 
reaction mixture was stirred for 48 h at room temperature and then 3 ml ethanol was 
added to react with the excess acetic anhydride.  The resultant mixture was poured 
into an ice-chloroform mixture and the acetylated product was extracted three times 
using liquid-liquid partitioning in a separating funnel.  The organic phases were 
combined and the solvent removed under vacuum.  Preparative TLC was used with 
chloroform-methanol (9:1 v/v) as the solvent system and compound 12 (2.1 mg) 
was obtained. 
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3.1.8 Accurate mass analysis 
Accurate mass analysis was performed on an UPLC high-definition quadrupole time-
of-flight mass spectrometer (MS) instrument (UPLC-qTOF SYNAPT G1 HDMS 
system, Waters, Manchester, UK) fitted with an Acquity BEH C8 column (2.1 x 150 
mm, 1.7 µm; Waters Corporation). 
For all the isolated compounds and fractions, the following method was followed for 
accurate mass evaluation.  A binary solvent system consisting of eluent A: 0.1% 
formic acid in water and B: 0.1% formic acid in methanol (Romil Chemistry, UK) was 
used at a constant column temperature of 60°C.  A 40 min gradient method at a 
constant flow rate of 0.4 mL/min was used for compound separation, and the 
conditions were: 10% B over 0.0-1.0 min, 10%-25% B over 1.0-3.0 min, 25%-30% B 
over 3.0-9.0 min, 30%-35% B over 9.0-10.0 min, 35%–80% B over 10.0 -35.0 min, 
80%-100% B over 35.0-35.1 min and held constant at 100% B over 35.1-37.0 min to 
wash the column.  Thereafter, the column was returned to initial conditions at 38 min 
and allowed to equilibrate for 2 min.  Chromatographic separation was monitored 
using a photodiode array (PDA) detector with a scanning range set between 200-500 
nm, 1.2 nm bandwidth resolution and a sampling rate of 20 points.sec-1.  
 
3.1.5.1 Quadrupole time-of-flight mass spectrometry (Q-TOF-MS)  
Post-PDA detection, the metabolites were further characterised with the aid of a 
SYNAPT G1 high definition mass spectrometer operating in positive and negative 
ionization modes.  The MS conditions were as follows: capillary voltage of 2.5 kV, 
sample cone voltage of 30 V, extraction cone voltage of 4 V, MCP detector voltage 
of 1600 V, source temperature of 120ºC, desolvation temperature of 450C, cone 
gas flow of 50 L/h, desolvation gas flow of 550 L/h, m/z range of 100-1000, scan time 
of 0.2 sec, interscan delay of 0.02 sec, mode set as centroid, lockmass set as 
leucine enkephalin (556.2771 / 554.2615 Da), lockmass flow rate of 0.1 mL/min, and 
mass accuracy window of 0.5 Da.  High purity nitrogen gas was used for desolvation, 
cone and collision gas.  The software used to control the hyphenated system was 
MassLynx Ver. 4.1 (SCN 704).  
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3.2 Results and Discussion 
In order to incorporate traditional medicines into the South African healthcare 
system, certain precautions need to be considered when verifying claimed medicinal 
activity.  These precautions include toxicity that may prevent immediate use of the 
claimed medicine (Moshi, 2005).  The activity of traditional medicine is attributed to 
secondary metabolites which are products of secondary chemical pathways in plants 
that are crucial for the survival of the plants in their natural environment (Hartmann, 
2007; Shaik et al., 2010).  Secondary metabolites provide a chemical defence 
against herbivores, insects, microorganisms and viruses (Wink, 2003).  These 
secondary metabolites include a variety of nitrogen-containing compounds including 
non-protein amino acids, cyanogenic glucosides and alkaloids and non-nitrogen 
compounds such as terpenoids, phenolics and steroids (Shaik et al., 2010).  In 
plants, secondary metabolites can be found in an active state or as a prodrug which 
is activated upon infection or wounding of the plant (Wink, 2003).   
Different geographic locations may result in a variation in the metabolic profiles of S. 
frutescens (Albrecht et al., 2012).  In this chapter the metabolite content of extracts 
obtained from plants growing in two different geographic environments was also 
assessed.  The metabolic profiles were obtained using UPLC-QTOF-MS 
 
3.2.1 Characterisation of isolated compounds 
3.2.1.1 Structural elucidation of 7S,24S,25-trihydroxycycloart-2-en-1-one 
(compound 10) 
At first viewing of the 13C-NMR spectrum (Appendix 1), 30 signals were observed 
indicating that this compound might be a steroid or triterpene.  A closer look at the 
spectrum showed an oxygen-bearing quaternary carbon signal at 𝛿C 74.04 (C-25), a 
carbonyl signal at 𝛿C 203.49 (C-1) and two oxygen-bearing methine signals at 𝛿C 
69.15 (C-7) and 𝛿C 79.89 (C-24). It also showed two olefinic carbon signals at 𝛿C 
129.66 (C-2) and 161.31(C-3). The 13C NMR chemical shift of this compound is 
collated in Table 1. 
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The 1H spectrum shows the presence of two olefin signals as doublets at 𝛿H 5.86 
(J=9.9 Hz) and 𝛿H 6.73 (J=9.9 Hz) assignable to H-2 and H-3 of a triterpene moiety.  
It further revealed two protons on oxygen-bearing carbons at 𝛿H 3.70 (broad 
multiplet) and 𝛿H 3.31 (broad doublet) with a coupling constant of J=9.0 Hz. Six 
tertiary methyl groups at 𝛿H 0.91(s, H-30), 𝛿H 0.96 (s, H-28), 𝛿H 0.98 (s, H-18), 𝛿H 
1.11 (s, H-26), 𝛿H 1.12 (s, H-29), 𝛿H 1.14 (s, H-27), one secondary methyl at 𝛿H 0.89 
(d, H-21, J=6.6 Hz), and cyclopropane methylene signal at 𝛿H 0.94 and 1.58 (each 
1H, J=4.8 and J=4.2) were observed.  These cyclopropane methylene signals are 
characteristics of a cycloartane-type structure. 
 
H OH
H
OH
H
O
OH
12
3 4
5
10
9
8
7
6
29
28
19
11
12
13
14
15
16
17
30
21
20
22
23
24
27
26
25
18
 
Figure 10: Structure of compound 10 
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Table 1: 1H- and 13C-NMR data of compound 10 in MeOH (600 MHz) 
Position Compound 10 
 𝜹C 𝜹H (J=Hz) 
1 203.49  
2 129.66 5.86 d (9.9) 
3 161.31 6.73 d (9.9) 
4 37.06  
5 42.85  
6 28.85 1.95 m 
7 69.15  
8 52.39  
9 50.49  
10 37.71  
11 34.81  
12 33.87  
13 46.52  
14 33.54  
15 26.47 2.00 m, 2.64 m 
16 31.06 1.24 m,1.92 m 
17 53.19  
18 15.97 0.98 s 
19a 29.23 0.94 d (4.5) 
19b  1.58 d (4.5) 
20 37.47  
21 19.18 0.89 d (6.6) 
22 29.04  
23 34.66 1.37 m, 1.61 m  
24 79.89  
25 74.04  
26 25.16 1.11 s 
27 25.78 1.14 s 
28 28.21 0.96 s 
29 21.51 1.12 s 
30 19.12 0.91 s 
 
The proton-proton correlation spectrum (COSY) revealed that compound 10 has the 
following partial structures (Figure 11).  The short range hydrogen-carbon correlation 
spectrum (HSQC) displayed the correlation of all protonated atoms with well 
resolved protons. 
These observed correlations were further substantiated by long range hydrogen- 
carbon 13 correlation (HMBC) (Figure 12).  Supplementary information is given in 
Appendix 1. 
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Figure 11: Structural fragments of compound 10 
 
Table 2: 1H-13C HMBC correlations of compound 10 
𝛿H 𝛿c 
(H-3) (C-1), (C-5), (C-28), (C-29)  
(H-2) (C-3) 
(H-7) (C-9) 
(H-8) (C-9), (C-13) 
(H-18) (C-12), (C-17) 
(H-19) (C-5), (C-8) 
(H-15) (C-8), (C-13) 
(H-21) (C-22), (C-17) 
(H-24) (C-22), (C-23),(C-27) 
(H-26) (C-24), (C-27) 
(H-27) (C-24), (C-26) 
(H-28) (C-29) 
(H-29) (C-28) 
(H-30) (C-8), (C-13) 
 
 
Figure 12: Key HMBC correlations associated with compound 10 
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The accurate mass obtained from the HRTOFMS spectra (Figure 13) confirmed the 
structural formula.  The ESI+ (positive mode) showed a pseudo molecular ion at m/z 
473.3631 (Calculated for [C30H48O4 + H]
+) and a sodium adduct at m/z 495.3450 
(calculated for [C30H48O4 + Na]
+).  The ESI- (negative mode) showed a formic acid 
adduct at m/z 517.3529 (calculated mass for [C30H48O4 - H+HCOOH]
-) due to its 
presence in the source.  Elementary analysis performed on the mass ions gave 
C30H49O4 and C31H51O6 (corresponding to [C30H48O4 + H]
+ and [C30H48O4 - H+ 
HCOOH]-) molecular formulas and both fragments had 0.0 i-FIT value, a mass error 
of 2.4 mDa and -2.4 mDa and the calculated double bond equivalence (DBE) values 
were 6.5 and 7.5.  The sodium adduct had an i-FIT value of 0.2, a mass error -0.1 
mDa, a calculated DBE value of 6.5 and the molecular formula was C30H48O4Na. 
Supplementary information is given in Appendix 2 
 
 
Figure 13: HRTOFMS spectrum (ESI- and ESI+) for compound 10 
 
From our literature searches conducted on this compound it appears that this 
compound has not been previously reported as per review in section 2.2.2.  
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3.2.1.2 Structural elucidation of the acetylated cycloartane (compound 11) 
The proton NMR spectrum revealed the presence of six acetate methyl peaks, a 
sugar moiety and a triterpene moiety (see appendix 3 for NMR spectra).  The six 
acetate methyl groups suggest that the compound might contain four acetate groups 
in the sugar moiety and two acetate methyl groups in the triterpene moiety.  It further 
revealed two olefin signals as doublets at 𝛿H 5.87 (J=9.8 Hz) and 𝛿H 6.58 (J=9.8 Hz) 
assignable to H-2 and H-3 of the triterpene moiety; two protons on oxygen-bearing 
carbons at 𝛿H 3.66 (broad multiplet) and 𝛿H 4.85.  Six tertiary methyl groups at 𝛿H 
0.88(s, H-30), 𝛿H 0.91 (s, H-18), 𝛿H 0.93 (s, H-29), 𝛿H 1.08 (s, H-28), 𝛿H 1.15 (s, H-
26), 𝛿H 1.19 (s,H-27), one secondary methyl at 𝛿H 0.82 (d, H-21, J=6.4 Hz), and 
cyclopropane methylene signal at 𝛿H 1.05 and 1.44 (each 1H, J=4.4 and J=4.8) were 
observed.  The presence of the cyclopropane methylene signals also suggested that 
this compound might be a cycloartane type. 
A 13C-NMR spectrum (Table 1) displayed 43 resonances with a characteristic 
oxygen-bearing quaternary carbon signal at 𝛿C 79.51 (C-25), a carbonyl signal at 𝛿C 
200.58 (C-1), two oxygen-bearing methine signals at 𝛿C 71.49 (C-7) and 𝛿C 78.62 
(C-24). It also showed two olefinic carbon signals at 𝛿C 129.25 (C-2) and 158.62 (C-
3).  Acetate carbon signals were observed in the range of 𝛿C 169.23 to 170.79 with 
their methyl carbon signal also ranging from 𝛿C 20.82 to 20.90. 
 
Figure 14: Structure of compound 11 
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Table 3: 1H- and 13C-NMR data of compound 11 in MeOH (600 MHz) 
Position Compound 11 
 𝛅C 𝛅H (J=Hz) 
1 200.58  
2 129.25 5.87 d (9.8) 
3 158.62 6.58 d (9.8) 
4 36.80  
5 41.31 2.33 dd (13.6, 4.0)  
6 26.70  
7 71.49  
8 48.16 2.22 d (4.8) 
9 31.24  
10 35.37  
11 25.10  
12 25.57  
13 49.15  
14 45.54  
15 33.86  
16 32.54  
17 51.51  
18 15.71 0.91 s 
19a 28.32 1.05 d (4.6) 
19b  1.44 d (4.6) 
20 35.89  
21 18.44 0.82 d (6.4) 
22 25.57  
23 27.59  
24 78.62  
25 79.51  
26 21.78 1.15 s 
27 24.48 1.19 s 
28 28.05 1.08 s 
29 21.25 0.93 s 
30 18.87 0.88 s  
1’ 95.72 4.69 d (8.0) 
2’ 71.79  
3’ 73.21 5.185 t (9.4) 
4’ 69.08  
5’ 71.89  
6’a 62.64 4.09 dd (12.0, 2.4) 
6’b  4.16 dd (12.0, 5.6) 
Acetates   
1(CH3) 20.82
  
2(CH3) 20.90
  
3 169.23  
4 169.67  
5 170.32  
6 170.51  
7 170.79  
 
32 
 
The 1H-13C HMBC (Table 4) spectrum revealed the following correlations (Figure 
10).  The position of the double bond at C2-C3 was supported by COSY correlation 
of H-2/H-3 and it also supported the presence of cyclopropane methylene by 
showing splitting hydrogen correlations at C-19 of H-19a/H-19b, the correlations of 
the hydrogen bonded to an oxygenated carbon C-7 and C-8 of H-7/H-8.  For the 
sugar moiety the following COSY correlations of H1'/H2', H2'/H3', H4'/H5', H5'/H6' 
were observed. 
 
 
Figure 15: Key HMBC correlations associated with compound 11 
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Table 4: 1H-13C HMBC correlations of acetylated compound 
𝜹H 𝜹c 
(H-3) (C-5), (C-1) 
(H-2) (C-10), (C-4) 
(H-8) (C-13), (C-10), (C-30) 
(H-11) (C-8) 
(H-18) (C-17) 
(H-19a/b) (C-8), (C-11), (C-5) 
(H-21) (C-16)  
(H-24) (C-27), (C-26) 
(H-26) (C-27) 
(H-27) (C-24) 
(H-28) (C-3), (C-29) 
(H-29) (C-3), (C-28) 
(H-30) (C-8), (C-9), (C-13); (C-7) 
(H-1') (C-2'), (C-25) 
(H-2') (C-1') 
(H-3') (C-2') 
(H-4') (C-3'); (C-6') 
 
The structural formula of this acetylated compound was confirmed by HRTOFMS 
and it also showed a molecular formula of C48H70O15.  The ESI
+ (positive mode) 
showed a pseudo molecular ion at m/z 887.4793 (calculated for [C48H70O15 + H]
+) 
and a sodium adduct at m/z 909.4612 (calculated for [C48H70O15 + Na]
+).  Elementary 
analysis performed on the mass ions gave C48H71O15 corresponding to [C48H70O15 + 
H]+ molecular formula and fragments had 0.2 i-FIT value, a mass error of 9.9 mDa 
and the calculated double bond equivalence (DBE) values were 13.5.  The sodium 
adduct had an i-FIT value of 0.1, a mass error 4.4 mDa, a calculated DBE value of 
4.5 and the molecular formula was C48H70O15Na.  HRTOFMS spectra (ESI
+) showed 
in Appendix 4 (pages 81-83). 
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3.2.1.3 Structural elucidation of compound 5 
Compound 5 exhibited 36 signals in the 13C NMR (Table 5) spectrum indicating a 
possibility of an aglycone moiety attached to a triterpene moiety.  Supplementary 
information is given in Appendix 5. 
In the 1H-NMR spectrum, three protons on oxygen-bearing carbons at 𝛿H 3.35 triplet, 
𝛿H 3.68 triplet (H-7) and 𝛿H 3.68 triplet (H-24) with coupling constants J=4.8, 4.8, 8.7 
Hz were observed. It further revealed six tertiary methyl groups at 𝛿H 0.89 (H-27), 𝛿H 
0.94 (s, H-30), 𝛿H 0.95 (s, H-18), 𝛿H 0.98 (s, H-28), 𝛿H 1.18 (s, H-29), 𝛿H 1.23 (s, H-
26), one secondary methyl at 𝛿H 0.89 (d, H-21, J=6.6 Hz). Interestingly, in the 
spectrum, splitting cyclopropane methylene signals at 𝛿H 0.73 and 1.41 (each 1H, d, 
J=4.8 and J=4.2) were observed and these cyclopropane methylene signals suggest 
that the triterpene is a cycloartane type. 
On the 13C NMR spectrum, characteristic oxygen bearing quaternary carbon signal 
was observed at 𝛿C 81.7 (C-25), a carbonyl signal at 𝛿C 213.5 (C-1), three oxygen-
bearing methine signals at 𝛿C 69.5 (C-7), 𝛿C 78.4 (C-3) and 𝛿C 78.9 (C-24).  
13C 
NMR indicated that compound 5 is a Sutherlandioside B triterpenoid also known as 
SU1 as described by Olivier et al., (2009)(Figure 16 and discussed in section 
2.2.2.5). 
 
Figure 16: Structure of compound 5 
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Table 5: 1H- and 13C-NMR data of compound 5 in MeOH (600 MHz) 
  Experimental Literature (Olivier et al. 
2009). 
Position 13C   13C   
1 213.5   213.0   
2 48.9 a: 2.96 dd (14.4, 5.4) 48.7 a: 3.01 dd (14.3, 4.5) 
  b: 2.37 dd (14.1,4.5)  b: 2.41 dd (14.3, 4.5) 
3 78.4 3.68 t (4.8) 78.8 3.75 t (4.8) 
4 40.2  40.1  
5 38.8 2.44 dd (13.5, 3.3) 38.6 2.48 dd (14.0, 3.6) 
6 31.0  30.8  
7 69.5 3.68 t (4.8) 69.3 3.75 m 
8 51.4 2.08 d (4.2) 51.2 2.12 d (3.6) 
9 30.8  30.6  
10 40.6  40.4  
11 29.1 1.86 m 29.0 1.88 m 
12 34.0  33.8 1.67(m), 1.53 d (3.0) 
13 46.6  46.4  
14 50.6  50.5  
15 34.5 1.36 m 34.4 1.39 td (10.5, 2.1) 
16 28.9 1.95 m 28.7 1.90 m 
17 53.2 1.64 m 53 1.68 td (9.3, 2.2) 
18 15.8 0.98 (s) 15.6 1.01 s 
19 24.9 a: 075 d (4.5) 24.6 a:0.78 d (4.5) 
  b: 1.43 d (4.5)  b:1.47 d (4.5) 
20 37.5 1.47 m 38.0 1.48 m 
21 19.2 0.91 d (6.0) 19.3 0.96 d (6.3) 
22 34.8 1.95 m 35.1 1.90 m 
23 29.1 1.64 m 29.3 1.68 m 
24 78.9  79.5 3.36 br d (9.3) 
25 81.7  81.9  
26 23.2 1.25 s 23.8 1.29 s 
27 21.9 1.21 s 21.3 1.26 s 
28 24.9 1.00 s 24.8 1.04 s 
29 22.7 0.97 s 21.7 0.97 s 
30 19.1 0.98 (s) 18.9 1.01 s 
1' 98.2 4.52 d (7.8) 98.6 4.56 d (7.8) 
2' 75.5 3.17 br t (8.4) 75.1 3.21 br t (7.8) 
3' 78.1 3.28 m 78.1 3.35 t (8.6) 
4' 71.8 3.37 m 71.6 3.38 m 
5' 77.9 3.28 m 77.7 3.32 m 
6' 62.9 a: 3.65 dd (11.7, 5.1) 62.6 a: 3.69 dd (11.9, 5.1) 
  b: 3.82 dd (12.0, 1.8)  b: 3.87 dd (11.7, 2.1) 
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The accurate mass obtained from the HRTOFMS spectra (Figure 17) is similar to 
that reported in the literature (Fu et al., 2008b; Olivier et al., 2009).  The ESI+ 
(positive mode) showed a pseudo molecular ion at m/z 653.4265 (calculated mass 
for [C36H60O10 + H]
+).  The ESI- (negative mode) showed a pseudo molecular ion at 
m/z 651.4108 (calculated mass for [C36H60O10 - H]
-) and a formic acid adduct 
(calculated mass for [C36H60O10 - H+ HCOOH]
-) at m/z 697.4163 due to its presence 
in the source.  Elementary analysis performed on the mass ions gave C36H61O10, 
C36H59O10 and C37H61O12 corresponding to [C36H60O10 + H]
+, [C36H60O10 - H]
- and 
[C36H60O10 - H+ HCOOH]
-) molecular formulas and for all the fragments i-FIT values 
were 0.0, a mass error of -3.9 mDa, -4.2 mDa and 2.5 mDa and the calculated 
double bond equivalence (DBE) values were 6.5, 6.5 and 7.5.  Supplementary 
information is given in Appendix 6 
 
 
Figure 17: HRTOFMS spectrum (ESI- and ESI+) for compound 5 
  
37 
 
3.3 Comparison of metabolite content of plant extracts. 
When the extracts from plants obtained in Paarl were compared with extracts 
obtained from plants from Petrusburg, the LC-MS elution profiles were similar with 
noticeable variation as to quantities of some of the metabolites. This is shown in 
figure 19 below. The profiles of extracts A and B were obtained from Petrusburg and 
Paarl, respectively while the profiles D and E involved plant material from Paarl and 
Petrusburg, respectively.  Elution profiles A and B involved ethanol extraction while 
D and E involved water extraction.  Comparison of A and B shows that compounds 
1, 2, 3 and 4 eluted separately and at higher relative concentration from Paarl plant 
material (B) relative to the corresponding metabolites from plant material obtained in 
Petrusberg (A). Conversely, the plant profiles obtained from water extraction from 
Petrusburg plant material showed an increased diversity and concentration relative 
to the Paarl plant material.  
The metabolites were more visible on the LC-ESI-MS negative mode and only five 
out of the eight biomarkers published by Avula et al. (2010) could be positively 
identified on the LC-MS spectra (Figure 19).  All the biomarkers isolated from S. 
frutescens are showed on Table 6.  Comparison of the electrospray ionisation 
negative mode with literature is presented on Table 7.  One triterpenoid was 
observed, namely the SU1 (compound 5) and it appeared to be the most dominant 
metabolite with varied quantities as compare to the other metabolites (see Table 6 
below for compound identification).  The SU1 elutes at approximately 10 min (Figure 
19).  The other four metabolites were flavanoids namely sutherlandins A to D.  
Sutherlandins A and B were found to co-elute at 7.71 min for the Petrusburg extracts 
and at approximately 7.6 min for the Paarl extracts.  Sutherlandins C and D were 
only observed from the Paarl extracts and they also co-eluted at 6.65 for the 99.9% 
ethanol and at 7.01 for the aqueous extracts.  In the aqueous extracts greater 
quantities of metabolites were observed in the polar region. 
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Figure 18: LC-MS metabolite profiles of extracts with the green ring representing compound 1 and 2; red ring representing 
compound 3 and 4; blue representing compound 5.  Extract A & B: 99% ethanol; extract D & E: distilled H2O. 
 
Extract E 
Extract D 
Extract B 
Extract A 
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Table 6: Compound Identification 
Compound 1: 
Sutherlandin A 
 
Compound 2: 
Sutherlandin B 
Compound 3: 
Sutherlandin C 
Compound 4: 
Sutherlandin D 
 
 
 
Compound 5: 
sutherlandioside B or SU1 
 
 
 
 
Compound 6: 
sutherlandioside A 
Compound 7: 
sutherlandioside C 
Compound 8: 
sutherlandioside D 
Compound9: SU3 
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Compound 10 Compound 11 
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Table 7: Comparison of the UPLC-MS data with literature (Avula et al., 2010b). 
Extract Compound 
 
ES
- 
ES
+ 
Accurate mass 
ES
- 
Molecular 
Formular 
A 
3 and 4 
723.1745 [M-H]
-
, 723.1784 [M-H]
- 
725.1918 [M+H]
+
, 747.1773 [M+Na]
+
 
725.1961 [M+H]
+
, 747.1791 [M+Na]
+
 
723.1773 [M-H]
-
 
C36H35O19 
C36H36O19 
5  651.4108 [M−H]
-
, 697.4188  
[M-H+ HCOOH]
-
 
653.4257 [M+H]
+
, 675.4117 [M+Na]
+
, 
653.4223 [M+H]
+
 
697.4215 
[M-H+ HCOOH]
- 
C37H61O12 
C36H60O10 
B 
1 and 2 739.1705 [M−H]
- 
739.1725 [M−H]
- 
741.1887 [M+H]
+
, 763.1739 [M+Na]
+ 
741.1941 [M+H]
+
, 763.1749 [M+Na]
+
 
739.1722 [M-H]
-
 
C36H35O19 
C36H36O19 
3 and 4 
723.1745 [M-H]
- 
723.1784 [M-H]
-
 
725.1918 [M+H]
+
, 747.1773 [M+Na]
+
 
725.1961 [M+H]
+
, 747.1791 [M+Na]
+
 
723.1816 [M-H]
-
 
C36H35O19 
C36H36O19 
5 and 11 651.4108 [M−H]
-
,  
697.4188 [M-H+ HCOOH]
- 
653.4257 [M+H]
+
, 675.4117 [M+Na]
+
 
653.4223 [M+H]
+
 
697.4197 
[M-H+ HCOOH]
-
 
C36H60O10 
C 
1 and 2 739.1705 [M−H]
- 
739.1725 [M−H]
-
 
741.1887 [M+H]
+
, 763.1739 [M+Na]
+ 
741.1941 [M+H]
+
, 763.1749 [M+Na]
+
 
739.1803 [M-H]
-
 
C36H35O19 
C36H36O19 
3 and 4 723.1745 [M-H]
- 
723.1784 [M-H]
-
 
725.1918 [M+H]
+
, 747.1773 [M+Na]
+
 
725.1961 [M+H]
+
, 747.1791 [M+Na]
+
 
723.1835 [M-H]
-
 
C36H35O19 
C36H36O19 
5  651.4108 [M−H]
-
 
697.4188 [M-H+ HCOOH]
- 
653.4257 [M+H]
+
, 675.4117 [M+Na]
+
 
653.4223 [M+H]
+
 
697.4152 
[M-H+ HCOOH]
- 
C37H61O12 
C36H60O10 
D 
3 and 4 723.1745 [M-H]
- 
723.1784 [M-H]
-
 
725.1918 [M+H]
+
, 747.1773 [M+Na]
+
 
725.1961 [M+H]
+
, 747.1791 [M+Na]
+
 
723.1780 [M-H]
-
 
C36H35O19 
C36H36O19 
5  651.4108 [M−H]
-
 
697.4188 [M-H+ HCOOH]
- 
653.4257 [M+H]
+
, 675.4117 [M+Na]
+
 
653.4223 [M+H]
+
 
697.4222 
[M-H+ HCOOH]
- 
C37H61O12 
C36H60O10 
E 
1 and 2 739.1705 [M−H]
- 
739.1725 [M−H]
-
 
741.1887 [M+H]
+
, 763.1739 [M+Na]
+ 
741.1941 [M+H]
+
, 763.1749 [M+Na]
+
 
697.4157 
[M-H+ HCOOH]
- 
C37H61O12 
C36H60O10 
3 and 4 723.1745 [M-H]
- 
723.1784 [M-H]
-
 
725.1918 [M+H]
+
, 747.1773 [M+Na]
+
 
725.1961 [M+H]
+
, 747.1791 [M+Na]
+
 
723.1782 [M-H]
-
 
C36H35O19 
C36H36O19 
5 651.4108 [M−H]
-
 
697.4188 [M-H+ HCOOH]
-
 
653.4257 [M+H]
+
, 675.4117 [M+Na]
+
 
653.4223 [M+H]
+
 
697.4155 
[M-H+ HCOOH]
-
 
C36H60O10 
A4 
3 and 4 723.1745 [M-H]
- 
723.1784 [M-H]
-
 
725.1918 [M+H]
+
,747.1773 [M+Na]
+
 
725.1961 [M+H]
+
,747.1791 [M+Na]
+
 
723.1757 [M-H]
-
 
C36H35O19 
C36H36O19 
5 651.4108 [M−H]
-
 
697.4188 [M-H+ HCOOH]
-
 
653.4257 [M+H]
+
, 675.4117 [M+Na]
+
 
653.4223 [M+H]
+
 
697.4180 
[M-H+ HCOOH]
-
 
C36H60O10 
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A3 
3 and 4 723.1745 [M-H]
-
, 723.1784 [M-H]
-
 725.1918 [M+H]
+
, 747.1773 [M+Na]
+
 
725.1961 [M+H]
+
, 747.1791 [M+Na]
+
 
723.1765 [M-H]
-
 
C36H35O19 
C36H36O19 
5 651.4108 [M−H]
-
 
697.4188 [M-H+ HCOOH]
-
 
653.4257 [M+H]
+
, 675.4117 [M+Na]
+
 
653.4223 [M+H]
+
 
697.4194 
[M-H+ HCOOH]
-
 
C36H60O10 
A2 5 651.4108 [M−H]
-
 
697.4188 [M-H+ HCOOH]
-
 
653.4257 [M+H]
+
, 675.4117 [M+Na]
+
 
653.4223 [M+H]
+
 
697.4158 
[M-H+ HCOOH]
-
 
C36H60O10 
Fraction 1 5 651.4108 [M−H]
-
 
697.4188 [M-H+ HCOOH]
-
 
653.4257 [M+H]
+
, 675.4117 [M+Na]
+
 
653.4223 [M+H]
+
 
697.4133 
[M-H+ HCOOH]
-
 
C36H60O10 
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3.4 Conclusion 
Sutherlandia frutescens plant material was collected from two different regions for 
comparison, namely from Petrusburg and Paarl.  Two different extraction methods 
(water and ethanol) were performed and five extracts (extract A-B) were obtained.  
Extract A was then subjected to further purification.  A novel compound (compound 
10), known compound (compound 5) and synthesised compound (compound 11) 
were isolated and characterised using chromatographic techniques and the chemical 
structures were confirmed by NMR and UPLC-MS.  Compound 10 was isolated from 
the DCM layer and shown to be an aglycone-type of cycloartane triterpenoid in 
contrast to the other two cycloartane glycosides (compound 5 and 11) isolated from 
the emulsion layer.  Compound 11 was an acetylated cycloartane glycoside. 
The LC-MS data showed similar metabolic profiles of the two regions with varied 
quantities of metabolites.   The profile obtained from the Paarl material extracted with 
ethanol showed higher quantities in comparison to the Petrusburg extracts whereas 
the profile of the Petrusburg material extracted with distilled water had more 
compounds at higher concentrations than the Paarl water extract.  Only five out of 
the eight biomarkers published by Avula et al. (2010) could be positively identified on 
the LC-MS spectra namely SU1 (compound 5) and sutherlandins A to D.  The above 
metabolites were more visible on the LC-ESI-MS negative mode. 
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CHAPTER 4:  PRELIMINARY BIOLOGICAL STUDIES 
4.1 Cell viability assay 
Sutherlandia frutescens gained its popularity in Africa due to the relatively long 
history of its usage.  However, it is also known to possess side effects such as dry 
mouth, mild diarrhoea, mild diuresis and dizziness in cachectic patients (Gericke et 
al., 2001; Mills et al., 2005b).  The recommended dose is two Sutherlandia tablets 
containing 300 mg (dried leaf powder) per day (Seier et al., 2002).  The current 
assay evaluates the cell viability of aqueous extracts and ethanol extracts obtained 
from S. frutescens plant material collected at two different locations. 
 
4.1.1 Methodology 
The cell viability assay was conducted at the CSIR Biosciences, Molecular Biology 
Platform and screened by Dr Lindiwe Thete.  To evaluate cytotoxicity of the plant 
compounds, 1x104 Vero cells/well were seeded in a 96 well plate for 24 hours to 
obtain 90% confluence.  Thereafter, the growth medium was removed and the cell 
monolayer was washed twice with phosphate buffered saline, pH 7,4 (PBS).  Each 
cell monolayer was then treated with an aliquot of 100 ug/ml of a plant extract 
benchmarked against a positive control (emetine) known to inhibit eukaryotic protein 
synthesis (Dimitrijevic and Duncan, 1998) included in duplicate wells at a 
concentration at 50 ug/ml.  The plate was then incubated for 3 days to evaluate 
potential cytotoxicity.  Cell viability was measured by using a 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) -2H-tetrazolium salt (MTS) 
assay kit (Promega Corporation, Madison, USA) according to the manufacturer’s 
instructions.  In this assay, the compound tetrazolium is converted into a blue 
formazan dye by metabolically active mitochondria of viable cells (Mosmann, 1983).  
At the end of the incubation period, cells were incubated with MTS solution for 2 h, 
and the absorbance was measured at 492 nm using a spectrophotometric microtitre 
plate reader (Infinite, F500, Tecan Group Ltd, Mannedorf, Switzerland).  The cell 
viability was expressed as a percentage relative to the control using the following 
equation: 
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Cell viability (%) = 100* (ODcmp/ODcntrl)   
 
where ODcmp is the optical density of the test compound and ODcntrl of the control 
(untreated cells). 
 
4.1.2 Results 
Extracts were toxic to the cells when initially tested for antiviral activity at a 
concentration of 1 mg/ml (data not shown).  The concentration of the extracts was 
then reduced to 100 ug/ml.  Two compounds (extracts A and B) showed similar 
levels of cytotoxicity as shown by the control cells treated with emetine.  The 
remaining compounds (extracts C, D and E) were not cytotoxic (Figure 20). 
 
E
xt
ra
ct
 A
E
xt
ra
ct
 B
E
xt
ra
ct
 C
E
xt
ra
ct
 D
E
xt
ra
ct
 E
E
m
et
in
e
0
50
100
150
%
 C
e
ll
 V
ia
b
il
it
y
 
Figure 19: Cytotoxicity of compounds at 100 ug/ml on Vero cells. Data expressed 
relative to control (untreated cells), mean, st dev, n=3.  Extract A & B: 99% ethanol; 
Extract C: 70% ethanol; Extract D & E: distilled H2O. 
 
From the above figure it is evident that aqueous extracts (extracts C, D and E) 
appear not to be toxic when compared to the cytotoxic effects of 99% ethanol 
extracts (A and B).  The toxicity of the latter two compounds was similar to that of the 
included emetine control.  The toxicity of extract C (extracted with 70% ethanol) is 
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intermediate between the cytotoxicity of extracts A and B and extracts D and E.  This 
confirms that cytotoxicity appears to decrease from non-aqueous to aqueous which 
might mean that the non-polar compounds are more likely to be toxic compared to 
the polar compounds. 
 
4.2 In vitro antiviral assay 
Herpes simplex virus (HSV) is an epitheliotropic virus infectious to children and 
adults (Danaher et al., 2011; Smith & Robinson, 2002).  During infection, HSV 
replicates and destroys cells at the portal entry and infection found in the epithelial 
cells results in de-envelopment, rapid replication and spread to adjacent cells and 
nerve endings (Danaher et al., 2011; Zhou et al., 2013).  In this study the antiviral 
potential of S. frutescens was evaluated by screening plant extracts against HSV-1. 
 
4.2.1 Methodology 
4.2.1.1 Solubility of compounds 
The solubility profiles and sample identification is presented on Table 1 below.  All 
compounds were dissolved and sonicated for an hour prior to experimental 
execution. 
 
Table 8: Sample identification and solubility profile of compounds 
Extract number Extract type Final concentration 
of solvent used 
Solubility 
SF-314-91601A 100% Ethanol 2.5% Ethanol Partly 
SF-314-91601B 100% Ethanol 2.5% Ethanol Soluble 
SF-314-91601C 70% Ethanol 1.75% Ethanol Soluble 
SF-314-91601D H2O H2O Soluble 
SF-314-91601E H2O H2O Soluble 
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4.2.1.2 Antiviral assay using Herpes simplex virus 1 
The antiviral assay was conducted at the CSIR Biosciences, Molecular Biology 
Platform and screened by Dr Lindiwe Thete.  Plant extracts were evaluated for 
antiviral activity using a cytopathic inhibitory method previously described by 
Schmidtke et al., (2001) to test the potency of plant extracts against herpes simplex 
virus 1.  Briefly, Vero cells (African green monkey kidney cell line, Cat No. CCL-81) 
purchased from ATCC (Manassas, VA) were seeded at 0.5x105 cells/well in 12 well 
plates for 24 hours to obtain 80%-90% monolayer confluence.  The culture media 
(199, Lonza, Cat no. BE12-117F) was supplemented with 10% fetal bovine serum 
(The Scientific Group, Cat. No. BC/S0615-HI, South Africa), 100 U/ml penicillin, and 
100 ug/ml streptomycin was removed and the monolayer was washed three times 
with PBS, pH 7,4 (Lonza, Cat. No. BE12-516F).  Then herpes simplex 1 MacIntyre 
strain (ATCC, Cat No. VR-539) was allowed to adsorb to the cells for 1 hour at a 
multiplicity of infection of 0.05 particle forming units.  Then, unadsorbed virus was 
removed and each of the cell monolayers was treated separately with 100 ug/ml of 
extracted compounds.  The positive control used in this assay was acyclovir at a 
concentration of 5 ug/ml, a drug that is used to treat symptomatic herpes simplex 
virus infection (Whitley & Gnann, 1992).  The plate was then incubated for 5 days to 
allow for the formation of virus-cytopathic effects (CPE).  Any CPE were measured 
by using an MTS assay kit (Promega Corporation, Madison, USA) according to the 
manufacturer’s instructions and as described above. 
The percentage of CPE inhibition was calculated by subtracting the mean value of 
virus-infected cell control (0%) from the measured absorbance, and the resulting 
number was divided by the measured absorbance of uninfected cell control (100%) 
using the equation below: 
CPE inhibition (%) = 100* [(ODcmp- ODvc/ODcmp)/ ODcc] 
where ODcmp is the optical density of the test compound, ODvc of the virus control 
and ODcc of cell control (untreated). 
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4.2.2 Results 
4.2.2.1. Antiviral activity 
None of the compounds showed significant activity (CPE inhibition >50%) against 
herpes simplex 1 virus (Figure 21). 
 
E
xt
ra
ct
 A
E
xt
ra
ct
 B
E
xt
ra
ct
 C
E
xt
ra
ct
 D
E
xt
ra
ct
 E
A
cy
cl
ov
ir
-100
-50
0
50
100
150
%
 C
P
E
 i
n
h
ib
it
io
n
 
Figure 20: Antiviral activity of compounds (100 ug/ml) and acyclovir (5 ug/ml) tested 
against Herpes simplex virus 1.  Data expressed relative to virus control.  Extract A & 
B: 99% ethanol; extract C: 70% ethanol; extract D & E: distilled H2O. 
 
The results presented in figure 21 correlate to an extent to the results of the 
cytotoxicity screening performed on the same extracts (section 5.1), where extract A 
and B were highly cytotoxic, similar in activity to the positive control (Figure 20).  The 
results of the experiment indicated values below zero after treating the cells and 
viruses with the two extracts (A and B).  This suggests that the two extracts had a 
cytocidal effect rather than an effect on virus replication (data not shown). 
The aqueous extract D provided limited protection against HSV infection around 20% 
compared to the acyclovir control and this warrants further analysis, particularly by 
testing cell protection against HSV-1 in various concentrations of this extract. 
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4.2.3. Conclusions and recommendations 
None of the extracts showed acceptable antiviral activity.  Figure 21 above showed 
that extracts A and B do not appear to have antiviral activity but, rather, may well 
contribute to cytotoxicity as was shown in figure 20.  Also the concentration of 
compounds in extracts is lower than the positive control which might be a 
contributing factor to the loss of activity.  In comparison to the acyclovir control, a 
relatively minor antiviral effect was shown by extracts C, D and E with extract D 
showing around 20% anti-HSV when compared to the control.  A future, closer 
investigation of the plant extraction process, including a determination of the 
concentration of each of the extracts, into the antagonistic and/or synergistic effects 
of the extracts relative to effect on virus replication might provide further insights into 
the antiviral activity of S. frutescens extracts.  
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4.3 Immunomodulation assay 
The immune-potentiating ability of compounds isolated from Sutherlandia frutescens 
was assessed using a flow cytometry-based, multiplex cytokine bead assay (CBA) 
system.  The BD CBA Human Th1/Th2/Th17 Cytokine kit was employed as it has 
more sensitive than the conventional ELISA kit and, together with flow cytometry, 
allows the researcher to rapidly quantify the expression of multiple cytokines from 
single samples in the presence of plant extracts and to generate a standard curve for 
each analyte.  The current study investigated the following interleukins (IL): IL-6 and 
IL-10 and tumour necrosis factor alpha (TNF-α). 
 
4.3.1 Materials and methods 
4.3.1.1 Blood sample preparation 
To test the effects of extracts of S. frutescens on the activity of immune cells, plant 
extracts were incubated with aliquots of whole blood and then tested for the 
expression of cytokines. Briefly, aliquots of whole blood (125 µl) were separately 
introduced into a 15 ml conical polypropylene (PP) tube and then 100 µg/ml of 
sample (plant extract, fraction or pure compounds) dissolved in 0.1% DMSO were 
added to each separate tube followed by growth medium (RPMI 1640) to make a 
final volume of 1250 µl.  A positive control was included in these experiments and 
consisted of 0.3 µg/ml phytohaemagglutin A (PHA).  Negative controls consisted of 
unstimulated controls containing the same amount of blood as other samples 
followed by the addition of an equal volume of solvent that had been used to dissolve 
the plant extract samples.  Then, RMPI 1640 was added to the experiment cells and 
the control tubes to make up a volume of 1250 µl.  The tubes were incubated at 37℃ 
in the presence of 5% carbon dioxide (CO2) and at 100% relative humidity for 3 
days.  On day 4, 500 µl of supernatant medium was removed from each tube and 
transferred into separate labelled Sarsted tubes and stored at -80℃. 
To harvest the cells, 2 mM EDTA was used and 15 ml sterile polypropylene Sterilin 
tubes were vortexed and incubated at room temperature (RT) for 10 min before 
being centrifuged at 450 g (1400 rpm) for 7 min at room temperature and the 
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supernatant decanted.  This was followed by the addition of 5 ml of phosphate buffer 
saline (PBS) to the pellet.  Then the tubes were centrifuged again and the 
supernatant discarded.  For cell (white blood cells) staining, a fixable viability dye 
was used, vortexed and incubated at room temperature for 20 minutes in the dark 
after which all steps were performed in the dark.  Then 5 ml of PBS with 1% fetal calf 
serum was added into the tubes followed by centrifugation at 450 g (1400 rpm) for 7 
minutes at RT and the supernatant was discarded.  Blood samples were lysed with 
1X FACSlyse solution in a ratio of 1:10 to the sample volume and then the tubes 
were vortexed well and incubated for 10 min at room temperature (RT). The tubes 
were then centrifuged at 600 g (1600 rpm) for 7 min at RT followed by decanting of 
the supernatant.  Cell pellets were re-suspended in 0.5-1 ml cryo-solution and 
transferred into appropriately labelled cryovials.  These tubes were then transferred 
into Mr Frosty containers and stored in a -80℃ freezer. 
 
4.3.1.2 Cytokine determination 
This assay was performed according to the BD CBA Cytokine Kit Assay procedure.  
A series of 0 to 5000 pg/ml standards were prepared by serial dilution in order to 
generate standard curves.  Then 50 µl of mixed captured beads, 50 µl of the human 
Th1/Th2/Th17 Cytokines Standard dilutions and 50 µl human Th1/Th2/Th17 
Phycoerythrin (PE) detection reagents were added consecutively into each sample 
tube and these were incubated for 3 h at room temperature in the dark.  After 
incubation, each sample was washed with 1 ml of wash buffer followed by 
centrifuging at 200 g for 5 minutes.  The supernatant was discarded and 300 µl wash 
buffer was added to each tube to resuspend the bead pellet. 
The experiment involving the flow cytometric analysis of the cytokines was 
performed in duplicate using a BD LSR FortessaTM flow cytometer at the University 
of the Witwatersrand.  Assistance was kindly provided by Mrs Patti Kay.  This flow 
cytometer was set up using cytometer setup beads (cat: 51-9005731; 1.5 ml) to 
obtain a target mean fluorescent intensity (MFI) of 72 for Allophycocyanin (APC), 69 
for PE and 71 for Fluorescein Isothiocyanate (FITC). Data were acquired using BD 
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FACSDiva software following which fcs files were transferred to FCAP Array (version 
3) software for analysis. 
 
4.3.2 Results and discussion  
Preliminary studies were conducted to assess any immune potentiation by S. 
frutescens extracts, fractions and compounds.  It was noted that some of the 
fractions and compounds only partially dissolved in 0.1% DMSO – these included 
extracts A3, A3Ac, B and Fraction 1, each at a concentration of 100 ug/ml.  Blood 
samples showed de novo elevated concentrations (pg/ml) of IL-6, IL-10 and TNF-α 
(Figure 22).  The elevation of the TNF-α confirms an observation reported by 
Estcourt et al., (1997) where a comparison was made between healthy blood donors 
and HIV-infected patients, and where the healthy donors had high concentration of 
TNF-α.  TNF-α and IL-6 have pro-inflammatory and pro-atherosclerotic actions that 
induce IL-10 which acts as an anti-atherosclerosis factor and as well as a pro-
inflammatory inhibitor.  This then suggests that cytokines may be counterbalanced 
by inhibitors or other cytokines with opposing effects (Stenvinkel et al., 2005).  The 
test subject in the current study tested negative for HIV. 
 
4.3.2.1 Analysis of figure 22. 
IL-6 analysis:  
There was not a large increase in IL-6 expression when comparing the positive 
control with the negative controls.  Thus, most of the samples showed little or no 
increase (immunopotentiation) or decrease (suppression) in IL-6 expression (Figure 
22A).  However, extracts C and D and compounds 10 and 11 prompted a relative 
increase in IL-6 expression while Fraction 1 and, to a lesser extent, compound 5 
showed a reduced IL-6 expression compared to the controls.  
IL-10 analysis: 
Figure 22B shows widespread suppression of IL-10 expression as indicated by the 
addition to the blood cells of many of the samples (extracts, fractions and 
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compounds.  The effect of addition of samples can be divided into three groups 
according to their ability to effect IL-10 expression:  Fraction 1 and compound 10 are 
effective suppressors of IL-10 expression; extracts A and B, extract A3 and A3 Ac 
and compound 5 and compound 11 show intermediate suppression of IL-10 
expression; significantly, extracts C, D and E appear to show an immunopotentiation 
effect. 
 
TNFα analysis: 
Compared to the control, most of the 11 test samples showed an 
immunosuppressive effect.  Only two (extract A and compound 10) showed no 
impact on the expression of TNFα as compared to the controls.  In determining 
relative immunosuppressive effects, four samples (extract B, extract A3 and A3 Ac, 
and fraction 1) appeared to exert the greatest suppressive effect on TNFα 
expression while the remaining 5 samples showed an intermediate effect on TNFα 
suppression. 
 
Figure 22C showed a relative increase in suppression of TNF-α compared to the 
suppression of IL-10 and this suppression was significantly greater than suppression 
of IL-6. The only really consistent result was that fraction 1, and possibly compound 
5, inhibited the expression of all three of these cytokines.  
In themselves, these results don’t appear to be very informative.  However, the 
regulation of expression of interleukins and factors associated with control 
mechanisms of the immune system is immensely complicated.  To make sense of 
the results of this part of this study perhaps requires correlation between the 
dynamics of interleukin expression and specific clinical data.  Such a correlation 
between in vitro serological results and the clinical picture may provide the key to 
insight into the immune response and contribute to a meaningful discussion of 
results such as these. 
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(C) Human TNF-
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Figure 21: Flow cytometric evaluation of IL-6, IL-10 and TNF-α.  Extract A & B: 99% 
ethanol; extract C: 70% ethanol; extract D & E: distilled H2O; extract A3: emulsion 
layer; extract A3 Ac: acetylated emulsion layer. 
 
4.3.3 Conclusion 
At a point in the homeostasis of any cell, differentiated or not, a dynamic profile of 
cytokines should be evident that reflects gene expression within the cell at that point 
in time.  This profile should adjust according to changes in homeostasis and to the 
cellular macro- and microenvironment, be these changes in response to normal 
physiology or due to pathology.      
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Of the three cytokines analysed in detail, IL-6 showed consistently high levels of 
expression except when in the presence of fraction 1, and to a lesser extent, 
compound 5. The plant compounds had a much greater impact on the other two 
cytokines, particularly TNFα, and their action appeared to be directed at reducing 
expression of these cytokines.  These cytokine profiles might result in a 
counterbalancing of cytokines by other cytokines or inhibitors (Stenvinkel et al., 
2005). 
The study did not provide sufficient evidence to support immune potentiating effects 
associated with de novo expression of cytokines in the blood cells.  An in-depth 
analysis of the three cytokines needs to be performed to assess any such 
relationship between the plant extracts, fractions or compounds and the dynamics of 
cytokine expression/repression.  Variation in data from flow cytometric analysis of 
the cytometric profiles against plant sample treatment might be attributed to partial 
solubility of some of the plant samples, the differences in the extraction methods 
used for each extract and, thus, differences in the polarities of the extraction 
solvents.  The other confounding factor is the ability or otherwise to correlate the 
results obtained in these in vitro experiments: plant extracts, fractions or compounds 
may be immunopotentiating in vivo regardless of the observed de novo expression of 
cytokines in the experimental blood cells. 
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CHAPTER 5:  GENERAL CONCLUSIONS 
Different extraction methods were perform using absolute ethanol (extract A and B), 
70% ethanol (extract C) or distilled H2O (extract D and E) in which only two 
extraction methods were used for plant material obtain in Paarl as compared to three 
extraction methods used for Petrusburg due to the amount of material obtained. 
Extract A (10 g, absolute ethanol extract from Petrusburg) was subjected to further 
purification using liquid-liquid partitioning, TLC and column chromatography with a 
variety of solvents (MeOH, distilled H2O hexane, DCM and EtOAC).  One novel, one 
known and one synthesised compound was isolated and characterised using 
chromatographic techniques and the chemical structures were confirmed by NMR 
and UPLC-MS. 
Preliminary biological studies were conducted to assess the activity of extracts, 
fractions or compounds.  Cell viability studies showed that the aqueous extracts 
were not toxic in comparison to the ethanol extracts which were highly toxic.  Extract 
C confirmed the observation that cytotoxicity decreases from non-aqueous to 
aqueous which might mean that the non-polar compounds are more likely to be toxic 
compared to the polar compounds.  In vitro antiviral studies also confirmed the 
results obtained in the cell viability studies and extracts A and B had no antiviral 
effect and might contribute to cytotoxicity.  De novo elevation of three cytokines was 
observed in the immune modulation assay.  Of all of the cytokines tested, three 
cytokines - Interleukin 6 (IL-6), Interleukin 10 (IL-10) and tumour necrosis factor 
alpha (TNF-α) – showed elevated expression.  A great variation in the cytokine 
profiles of the samples was also observed from the flow cytometric analysis.  This 
variation suggested that extracts from Sutherlandia may be immunopotentiating 
regardless of the de novo expression of cytokines in the blood cells.  
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CHAPTER 6:  RECOMMENDATIONS 
Further studies involving the purification, isolation and characterisation of bioactive 
compounds from all the extracts need to be conducted.  This may be followed by an 
in-depth analysis of cytokines to confirm the results obtained above and assess any 
relationship between the plant extracts, fractions and compounds, and also the 
dynamics of cytokine expression/repression. It may be useful to perform a study that 
involves a meta-analysis of published data regarding the expression/suppression of 
cytokines in cells and to develop software that may be used to statistically determine 
relationships linking variously reported cytokine expression data so as to provide 
insights into the dynamics behind cytokine expression/repression.  
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Appendix Figure 22: HRTOFMS spectrum (ESI- and ESI+) for compound 10 (refer to page 29) 
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Appendix Figure 23: HRTOFMS spectrum (ESI- and ESI+) for compound 5 (refer to page 36) 
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